Paper42420577
Co-targeting TWIST1 and JUNB suppresses CCL2-induced cell motility and hybrid EMT in ESCC models.
Ling Z and 5 others. Commun Biol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Co-targeting TWIST1 and JUNB suppresses CCL2-induced cell motility and hybrid EMT in ESCC models. Papers, record 42420577. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42420577
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Co-targeting TWIST1 and JUNB suppresses CCL2-induced cell motility and hybrid EMT in ESCC models.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Twist-Related Protein 1 | Major topic |
| Epithelial-Mesenchymal Transition | Major topic |
| Chemokine CCL2 | Major topic |
| Cell Movement | Major topic |
| Nuclear Proteins | Major topic |
| Transcription Factors | Major topic |
| Esophageal Squamous Cell Carcinoma | Major topic |
| Esophageal Neoplasms | Major topic |
| Animals | |
| Humans | |
| Cell Line, Tumor | |
| Mice | |
| Zebrafish | |
| Signal Transduction | |
| Gene Expression Regulation, Neoplastic |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82270975 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 82401110 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 202206080009 | Guangzhou Science and Technology Program key projects | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38342234 | Single-cell transcriptomic analysis reveals the landscape of epithelial-mesenchymal transition molecular heterogeneity in esophageal squamous cell carcinoma. | Cancer Lett | 2024 | https://conductscience.org/library/papers/38342234 | PubMed |
| 2 | 34809669 | TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34809669 | PubMed |
| 3 | 33972779 | Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. | Nat Genet | 2021 | https://conductscience.org/library/papers/33972779 | PubMed |
| 4 | 38769475 | LINC00330/CCL2 axis-mediated ESCC TAM reprogramming affects tumor progression. | Cell Mol Biol Lett | 2024 | https://conductscience.org/library/papers/38769475 | PubMed |
| 5 | 34464477 | Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. | Cell Prolif | 2021 | https://conductscience.org/library/papers/34464477 | PubMed |
| 6 | 35177591 | Targeting CCL2-CCR4 axis suppress cell migration of head and neck squamous cell carcinoma. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35177591 | PubMed |
| 7 | 36782089 | Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/36782089 | PubMed |
| 8 | 33603224 | Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. | Nat Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33603224 | PubMed |
| 9 | 35791509 | Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. | Cancer Commun (Lond) | 2022 | https://conductscience.org/library/papers/35791509 | PubMed |
| 10 | 39414946 | Two distinct epithelial-to-mesenchymal transition programs control invasion and inflammation in segregated tumor cell populations. | Nat Cancer | 2024 | https://conductscience.org/library/papers/39414946 | PubMed |
| 11 | 37005490 | Tumor microenvironment signaling and therapeutics in cancer progression. | Cancer Commun (Lond) | 2023 | https://conductscience.org/library/papers/37005490 | PubMed |
| 12 | 37926835 | MYL9 expressed in cancer-associated fibroblasts regulate the immune microenvironment of colorectal cancer and promotes tumor progression in an autocrine manner. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37926835 | PubMed |
| 13 | 38503384 | Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy. | Semin Cancer Biol | 2024 | https://conductscience.org/library/papers/38503384 | PubMed |
| 14 | 38457759 | Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38457759 | PubMed |
| 15 | 39334513 | Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma. | Biomark Res | 2024 | https://conductscience.org/library/papers/39334513 | PubMed |
| 16 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 17 | 40105813 | Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma. | JAMA Surg | 2025 | https://conductscience.org/library/papers/40105813 | PubMed |
| 18 | 27055731 | Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27055731 | PubMed |
| 19 | 38864342 | Identification and Characterization of Metastasis-Initiating Cells in ESCC in a Multi-Timepoint Pulmonary Metastasis Mouse Model. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38864342 | PubMed |
| 20 | 37259089 | EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin? | Mol Cancer | 2023 | https://conductscience.org/library/papers/37259089 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42420577
GET https://conductscience.org/api/papers/v1/42420577/references?page=2